Publication | Open Access

The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy

21-Gene Recurrence ScoreBreast OncologyMedicineCancer ManagementAdjuvant ChemotherapyGynecologyBreast CancerCancer TreatmentOncologyRadiation OncologyUnified Treatment PolicyCancer Research